ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2020, 'Patterns of drug and alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis c virus treatment with directacting antiviral therapies: An international study', Clinical Infectious Diseases, 70, pp. 2369 - 2376, http://dx.doi.org/10.1093/cid/ciz633
,2020, 'Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation', Gastroenterology Clinics of North America, 49, pp. 253 - 277, http://dx.doi.org/10.1016/j.gtc.2020.01.005
,2020, 'Universal screening for hepatitis C virus infection should be linked to universal treatment access', Nature Reviews Gastroenterology and Hepatology, 17, pp. 321 - 322, http://dx.doi.org/10.1038/s41575-020-0306-8
,2020, 'Hepatitis C elimination in Australia: progress and challenges', Medical Journal of Australia, 212, pp. 362 - 363, http://dx.doi.org/10.5694/mja2.50584
,2020, 'Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis', Journal of Hepatology, 72, pp. 643 - 657, http://dx.doi.org/10.1016/j.jhep.2019.11.012
,2020, 'Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study', Journal of Viral Hepatitis, 27, pp. 281 - 293, http://dx.doi.org/10.1111/jvh.13233
,2020, 'Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting', International Journal of Drug Policy, 77, http://dx.doi.org/10.1016/j.drugpo.2020.102693
,2020, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial', Journal of Hepatology, 72, pp. 431 - 440, http://dx.doi.org/10.1016/j.jhep.2019.10.010
,2020, 'Global elimination of hepatitis C virus by 2030: why not?', Nature Medicine, 26, pp. 157 - 160, http://dx.doi.org/10.1038/s41591-019-0706-x
,2020, 'Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—The practitioner experience', Drug and Alcohol Dependence, 206, http://dx.doi.org/10.1016/j.drugalcdep.2019.107705
,2020, 'Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 among Human Immunodeficiency Virus-positive Gay and Bisexual Men?', Clinical Infectious Diseases, 70, pp. 106 - 113, http://dx.doi.org/10.1093/cid/ciz164
,2020, 'Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV', AIDS, 34, pp. 1347 - 1358, http://dx.doi.org/10.1097/QAD.0000000000002562
,2020, 'Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C Infection', Clinical Infectious Diseases, 70, pp. 123 - 131, http://dx.doi.org/10.1093/cid/ciz162
,2020, 'Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma', Alimentary Pharmacology and Therapeutics, 51, pp. 34 - 52, http://dx.doi.org/10.1111/apt.15598
,2019, 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms', Scientific Reports, 9, http://dx.doi.org/10.1038/s41598-018-35736-2
,2019, 'Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study', Journal of Viral Hepatitis, 26, pp. 1423 - 1430, http://dx.doi.org/10.1111/jvh.13196
,2019, 'Reply to: “Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis”', Journal of Hepatology, 71, pp. 1254 - 1255, http://dx.doi.org/10.1016/j.jhep.2019.07.011
,2019, 'The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination', Clinical Infectious Diseases, 69, pp. 2218 - 2227, http://dx.doi.org/10.1093/cid/ciz714
,2019, '‘Fighting a losing battle’: prisoners’ perspectives of treatment as prevention for hepatitis C with inadequate primary prevention measures', Drugs: Education, Prevention and Policy, 26, pp. 502 - 507, http://dx.doi.org/10.1080/09687637.2018.1494135
,2019, 'Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection', Journal of Viral Hepatitis, 26, pp. 1301 - 1310, http://dx.doi.org/10.1111/jvh.13175
,2019, 'An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study', International Journal of Drug Policy, 72, pp. 99 - 105, http://dx.doi.org/10.1016/j.drugpo.2019.07.002
,2019, 'Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care', Journal of Hepatology, 71, pp. 699 - 706, http://dx.doi.org/10.1016/j.jhep.2019.05.033
,2019, 'Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia', Journal of Hepatology, 71, pp. 281 - 288, http://dx.doi.org/10.1016/j.jhep.2019.04.014
,2019, 'Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study', Journal of Viral Hepatitis, 26, pp. 969 - 979, http://dx.doi.org/10.1111/jvh.13112
,2019, 'Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing', Infection, Genetics and Evolution, 71, pp. 36 - 41, http://dx.doi.org/10.1016/j.meegid.2019.02.032
,2019, 'HCV reinfection as a positive indication of high-risk population treatment access', Journal of Viral Hepatitis, 26, pp. 516 - 518, http://dx.doi.org/10.1111/jvh.13092
,2019, 'A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections', Infection, Genetics and Evolution, 69, pp. 76 - 84, http://dx.doi.org/10.1016/j.meegid.2019.01.016
,2019, 'Genomic variability of within-host hepatitis C variants in acute infection', Journal of Viral Hepatitis, 26, pp. 476 - 484, http://dx.doi.org/10.1111/jvh.13051
,2019, 'Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1–6 receiving opioid substitution therapy', International Journal of Drug Policy, 66, pp. 73 - 79, http://dx.doi.org/10.1016/j.drugpo.2019.01.011
,2019, 'Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection', JOURNAL OF HEPATOLOGY, 70, pp. E231 - E231, http://dx.doi.org/10.1016/S0618-8278(19)30432-3
,2019, 'Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study', JOURNAL OF HEPATOLOGY, 70, pp. E110 - E110, http://dx.doi.org/10.1016/S0618-8278(19)30196-3
,2019, 'The consensus hepatitis C cascade of care: Methodology and initial findings from three countries', JOURNAL OF HEPATOLOGY, 70, pp. E333 - E334, http://dx.doi.org/10.1016/S0618-8278(19)30651-6
,2019, 'A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015', Journal of the International AIDS Society, 22, pp. e25222, http://dx.doi.org/10.1002/jia2.25222
,2019, 'Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission', The Lancet Gastroenterology and Hepatology, 4, pp. 135 - 184, http://dx.doi.org/10.1016/S2468-1253(18)30270-X
,2019, 'Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia', Journal of Hepatology, 70, pp. 33 - 39, http://dx.doi.org/10.1016/j.jhep.2018.09.030
,2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
,2019, 'Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies', Drug and Alcohol Dependence, 194, pp. 487 - 494, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.007
,2019, 'Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs', Addiction, 114, pp. 150 - 166, http://dx.doi.org/10.1111/add.14393
,2019, 'SAT-232-Reinfection following successful HCV DAA therapy among people with recent injecting drug use', Journal of Hepatology, 70, pp. e732 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31465-3
,2019, 'SAT-233-Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review, meta-analysis, and meta-regression', Journal of Hepatology, 70, pp. e733 - e733, http://dx.doi.org/10.1016/s0618-8278(19)31466-5
,2019, 'SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia', Journal of Hepatology, 70, pp. e734 - e734, http://dx.doi.org/10.1016/s0618-8278(19)31468-9
,2018, 'Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study', International Journal of Drug Policy, 62, pp. 14 - 23, http://dx.doi.org/10.1016/j.drugpo.2018.08.013
,2018, 'Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy', International Journal of Drug Policy, 62, pp. 94 - 103, http://dx.doi.org/10.1016/j.drugpo.2018.10.004
,2018, 'Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison', Journal of Viral Hepatitis, 25, pp. 1526 - 1532, http://dx.doi.org/10.1111/jvh.12987
,2018, 'Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia', International Journal of Drug Policy, 61, pp. 23 - 30, http://dx.doi.org/10.1016/j.drugpo.2018.08.011
,2018, 'Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 3, pp. 754 - 767, http://dx.doi.org/10.1016/S2468-1253(18)30304-2
,2018, 'Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials', Open Forum Infectious Diseases, 5, pp. ofy248, http://dx.doi.org/10.1093/ofid/ofy248
,2018, 'The removal of DAA restrictions in Europe – One step closer to eliminating HCV as a major public health threat', Journal of Hepatology, 69, pp. 1188 - 1196, http://dx.doi.org/10.1016/j.jhep.2018.06.016
,2018, 'Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection', Journal of Viral Hepatitis, 25, pp. 1180 - 1188, http://dx.doi.org/10.1111/jvh.12917
,2018, 'Erratum: Antiretroviral use in the CEASE cohort study and implications for direct-acting antiviral therapy in human immunodeficiency virus/hepatitis C virus coinfection (Open Forum Infect Diss (2016)3:2(ofw105) DOI: 10.1093/ofid/ofw105)', Open Forum Infectious Diseases, 5, http://dx.doi.org/10.1093/ofid/ofy033
,